← FDA DRUG APPROVALS

FDA ANDA · ANDA074332

BUMETANIDE

Sponsor: HOSPIRA

APPLICATION
ANDA074332
TYPE
ANDA
ORIGINAL APPROVAL
1994-10-31
LATEST ACTION
2020-07-01
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

BUMETANIDEDiscontinued
BUMETANIDE 0.25MG/ML · INJECTABLE · INJECTION

Approval history

2020-07-01Labeling · Supplement 15 · standardAP
2005-01-27Labeling · Supplement 8AP
2001-02-14Manufacturing (CMC) · Supplement 5AP
1998-06-01Labeling · Supplement 4AP
1997-07-09Manufacturing (CMC) · Supplement 2AP
1997-07-09Labeling · Supplement 3AP
1996-08-15Manufacturing (CMC) · Supplement 1AP
1994-10-31OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →